0
0
February 4, 2024
A recent study has introduced a promising development in the fight against microvascular diabetic complications, such as diabetic eye and kidney diseases, in individuals with diabetes. The research, published in the journal Cardiovascular Diabetology, highlights the potential of a new type of inhibitor drug in preventing life-altering consequences associated with this prevalent global disease.
Diabetes, characterized by uncontrolled blood glucose levels, affects approximately one in every 11 individuals worldwide. Despite available treatments, the disease can lead to severe complications by impacting the body’s small blood arteries, known as the microvasculature.
The study reveals that existing treatments for microvascular complications, like diabetic eye and kidney diseases, do not entirely delay progression, ultimately resulting in blindness and kidney failure in some patients. The research team focused on the glycocalyx, the protective lining of all blood vessels, which is known to be damaged in diabetes.
In two mouse models, the researchers demonstrated that by preventing damage to this protective layer, the development of diabetic eye and kidney diseases could be halted. Dr. Rebecca Foster, Associate Professor at the Bristol Medical School: Translational Health Sciences (THS) in the UK and senior author of the study, expressed excitement about the findings, stating, “Our findings are exciting as we have shown that one type of medication might be able to prevent different diabetic complications, which is a global health problem for adults living with diabetes.”
The study utilized a ‘heparanase inhibitor’ to achieve this breakthrough. Heparanase, acting like a pair of scissors, damages the glycocalyx lining, and heparanase inhibitors effectively prevent this damage. The researchers have developed a novel class of these inhibitors, offering hope for successful development into a medication for treating patients.
Dr. Monica Gamez, Research Associate in the Bristol Medical School (THS) and corresponding author, stated, “We are currently conducting research to advance our novel class of inhibitors to clinical use. With over 8 per cent of the global adult population currently living with diabetes, we hope patients could benefit from our findings in the future.”
This groundbreaking research marks a significant step forward in diabetes management, offering potential solutions to prevent complications and improve the quality of life for individuals grappling with this widespread health concern. As the development of these inhibitors progresses, it holds promise for transforming the landscape of diabetes care on a global scale.
